This phenotype is hereditary, more invasive, affects younger women, and has a much poorer prognosis than other phenotypes.[2] Triple negative breast cancers are refractory to the treatment options available for other hormone-independent breast cancers, which are negative for estrogen receptor and progesterone receptor but positive for Her2. This evidence concerns the gene ERBB2 and breast cancer.